Literature DB >> 5773814

The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

W H Clark, L From, E A Bernardino, M C Mihm.   

Abstract

Entities:  

Mesh:

Year:  1969        PMID: 5773814

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  296 in total

1.  Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma.

Authors:  R D Ramirez; S D'Atri; E Pagani; T Faraggiana; P M Lacal; R S Taylor; J W Shay
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

2.  Cutaneous malignant melanoma.

Authors:  S T Norvell; A J Bodurtha
Journal:  Can Fam Physician       Date:  1985-06       Impact factor: 3.275

3.  Selection of the optimum surgical treatment of stage I melanoma by depth of microinvasion: Use of the combined microstage technique (Clark-Breslow).

Authors:  H J Wanebo; J G Fortner; J Woodruff; B MacLean; E Binkowski
Journal:  Ann Surg       Date:  1975-09       Impact factor: 12.969

4.  Increased incidence of malignant melanoma of the skin in workers in a telecommunications industry.

Authors:  L De Guire; G Theriault; H Iturra; S Provencher; D Cyr; B W Case
Journal:  Br J Ind Med       Date:  1988-12

5.  Some properties of Bomirski Ab amelanotic melanoma cells, which underwent spontaneous melanization in primary cell culture. Growth kinetics, cell morphology, melanin content and tumorigenicity.

Authors:  A Słomiński
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

6.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

7.  Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features.

Authors:  K Pham; T Milovanovic; R J Barr; T Truong; R F Holcombe
Journal:  Mol Pathol       Date:  2003-10

8.  Adjuvant BCG immunotherapy for malignant melanoma.

Authors:  A H Paterson; D J Willans; L M Jerry; J Hanson; T A McPherson
Journal:  Can Med Assoc J       Date:  1984-10-01       Impact factor: 8.262

9.  A LY-15, a novel cyclic pentapeptide that inhibits B16 cell proliferation and migration and induces cell apoptosis.

Authors:  Xuan Wang; Xiangli Yao; Shiming Fan; Chenshuang Xiang; Runjiao Liu; Juan Feng; Jing Huang; Shouxin Liu
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

10.  The role of Bcl-2 family members in the progression of cutaneous melanoma.

Authors:  Jason A Bush; Gang Li
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.